Because SARS-CoV-2 uses the nasal cavity as a major route of entry to the human body, nasal administration of drugs and antibodies directed against the virus can prove to be effective for not only pulmonary COVID-19 but also prevention of potential early neuroinvasion caused by this virus. With recent reports of the potential application of antibody-laden nasal spray for the treatment of COVID-19, proposed here is the use of drugs recently proven to be effective against SARS-CoV-2 to be administered via inhalation route using a modified transcribrial device reported previously for its use against Naegleria fowleri, to target SARS-CoV-2 in our fight against COVID-1.